Article ID Journal Published Year Pages File Type
4000850 Urologic Oncology: Seminars and Original Investigations 2010 7 Pages PDF
Abstract

ObjectiveThe efficacy and tolerability of M-TIP was evaluated as first-line treatment for patients with poor-risk germ cell tumors (GCT), according to International Germ Cell Cancer Collaborative Group (IGCCCG) criteria.Patients and methodsThirty patients with poor-risk GCT were treated with M-TIP (methotrexate 250 mg/m2 given as a 4-hour infusion with folinic acid rescue on day 1, paclitaxel 175 mg/m2 given as a 3-hour infusion on day 1, followed by ifosfamide 1.2 g/m2 given as a 2-hour infusion and cisplatin 20 mg/m2 given as a 2-hour infusion on days 2 to 6) regimen for four cycles.ResultsFive (16.6%, 95% confidence interval [CI]: 2%–31%) patients achieved clinical complete response (cCR) with chemotherapy only, 15 (50%, 95% CI: 31–69%) patients pathologic complete response (pCR) (11 had necrosis/fibrosis and 4 had mature teratoma) and 3 (10%) patients surgical complete response (sCR) for an overall favorable response of 76.6%. Twenty-one patients are continuously disease-free at a median follow-up of 5.3 years (range 0.9–8.4+ years), resulting in a 5-year progression-free survival (PFS) rate of 66.6% (95% CI = 49%–85%) and a 5-year survival rate of 70% (95% CI = 53%–87%). Toxicity was generally mild except for myelotoxicity. Patients with febrile neutropenia were successfully treated with broad spectrum antibiotics and G-CSF support. Hematologic toxicity in this trial was ameliorated with the use of G-CSF. Neurotoxicity and nephrotoxicity were not a problem, since only 6.6% and 3.3% of patients developed sensory neuropathy and renal toxicity, respectively.ConclusionM-TIP is a highly effective (high proportion of patients achieved long-term disease-free status, lack of relapses) and well tolerated regimen for first-line treatment of poor-risk GCT patients. These results have to be compared with the standard BEP chemotherapy or more intensive regimens in multicentre randomized trials.

Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , ,